HHMI Investigator Kevan Shokat and his lab are charting new therapies to outmaneuver drug resistance and better target common cancer cell mutations.
Long-term outcomes of neoadjuvant chemotherapy (NAC) before bladder-sparing chemoradiotherapy (CRT) for patients with nonmetastatic muscle-invasive bladder cancer (MIBC). This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results